CP RELIEF WAND

K133779 · Mid-America Medical Innovations, LLC · GZJ · May 30, 2014 · Neurology

Device Facts

Record IDK133779
Device NameCP RELIEF WAND
ApplicantMid-America Medical Innovations, LLC
Product CodeGZJ · Neurology
Decision DateMay 30, 2014
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 882.5890
Device ClassClass 2
AttributesTherapeutic

Intended Use

The CP Relief Wand® CP-1000 is a TENS Device and is intended for use as an adjunctive therapy for pain management for medical purposes such as symptomatic relief of chronic intractable pain and relief of acute post-surgical and post-traumatic pain.

Device Story

Portable, hand-held TENS device; powered by 9V alkaline battery. Operates by applying electrical pulses to skin via gel-pad-covered electrodes positioned over pain centers. Pulses travel through skin and underlying nerve tissue to desensitize nerves. User-adjustable controls for power, intensity, pulse width, and pulse polarity. Used for pain management; intended for prescription use.

Clinical Evidence

Bench testing only. Functional and design verification and validation performed. Side-by-side testing conducted against predicate devices to compare waveforms and ensure compliance with IEC 60601-1, IEC 60601-1-2, and IEC 60601-2-10 standards.

Technological Characteristics

Portable TENS stimulator; 9V alkaline battery powered. Hand-held form factor with integrated electrodes and gel pads. Materials comparable to PALS® Neurostimulation Electrodes (K132422). Complies with IEC 60601-1, IEC 60601-1-2, and IEC 60601-2-10. No software/algorithm mentioned.

Indications for Use

Indicated for adjunctive therapy for pain management, specifically symptomatic relief of chronic intractable pain and relief of acute post-surgical and post-traumatic pain.

Regulatory Classification

Identification

A transcutaneous electrical nerve stimulator for pain relief is a device used to apply an electrical current to electrodes on a patient's skin to treat pain.

Predicate Devices

Related Devices

Submission Summary (Full Text)

{0} K133779/S002 23MAY2014 Additional Deficiencies Request Response Page 1 of 2 # 510(k) SUMMARY (per 21 CFR 807.92) MAY 30 2014 Date: December 11, 2013 Premarket Notification: K133779 Trade Name: CP Relief Wand® Model CP-1000 Sponsor: Mid-America Medical Innovations, LLC 1709 Honey Creek Road Jefferson City, MO 65101 Contact Person: Norm Schroeder Mid-America Medical Innovations, LLC 2704 Industrial Drive Jefferson City, MO 65109 Phone: 573-496-3213 Fax: 573-496-4015 Common Name: Transcutaneous Electrical Nerve Stimulator Classification Name: Stimulator, Nerve, Transcutaneous. For pain relief Device Classification: Class II Regulation: 21 CFR 882.5890 Device Product Code: GZJ Device Description: The CP Relief Wand® Model CP-1000 is a portable hand held TENS device with self-contained electrodes. The device is powered by a standard 9 volt alkaline battery. In operation, the electrode end of the CP-1000 is covered by a gel pad and positioned to touch the skin over the pain center. The electrical pulses travel from one electrode, through the skin, through the underlying nerve tissue, and back through the skin to the other electrode to desensitize the underlying nerves within the current path. Convenient controls on the unit are provided for power, intensity, pulse width, and pulse polarity. The materials comprising the gel pad and CP1000 electrodes are comparable to the materials comprising Axelgaard's PALS® Neurostimulation Electrodes cleared per K132422. Intended Use: The CP Relief Wand® CP-1000 is a TENS Device and is intended for use as an adjunctive therapy for pain management for medical purposes such as symptomatic relief of chronic {1} K133779/S002 23MAY2014 Additional Deficiencies Request Response Page 2 of 2 intractable pain and relief of acute post-surgical and post-traumatic pain. ## Predicate Devices: TENS 3000 Stimulator (K102014) InterX5000 (K042912) ## Technological Characteristics: The CP Relief Wand® Model CP-1000 possesses similar technological characteristics as the predicate device, including intended use, basic design, use of materials established as safe, and performance. The primary differences are in the use of fewer modes, fewer channels, and slight differences in performance parameters. These differences between the CP Relief Wand® Model CP-1000 and the predicates do not affect the safety and effectiveness of the device. The differences in design result in a less complex device than the predicates and do not affect safety and effectiveness of the device. The slight differences in performance parameters are negligible and do not affect safety and effectiveness of the device. Performance testing was conducted to compare the waveforms and to establish conformance with IEC 60601-1, IEC 60601-1-2, and IEC 60601-2-10. ## Performance Data: Performance testing of the CP-1000 has been conducted for functional and design verification and validation. Side by side testing was also performed for comparison with the predicate device. The testing indicates the device is substantially equivalent to the predicate device and is in compliance with the following recognized consensus standards: - IEC60601-1 Edition 2:1988 (A1:1991 + A2:1995) Medical Electrical Equipment; Part 1: General Requirements for Safety and Essential Performance - IEC60601-1-2:2007 Third Edition, Medical electrical equipment – Section 1.2 Collateral standard: Electromagnetic compatibility – Requirements and tests - IEC60601-2-10 (1987) and Amendment 1 (2001) Medical Electrical Equipment – Part 2-10: Particular requirement for the basic safety and essential performance of nerve and muscle stimulators ## Conclusion: The CP Relief Wand® is substantially equivalent to the TENS 3000 Stimulator and InterX5000 {2} DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002 May 30, 2014 Mid-American Medical Innovations, LLC Norm Schroeder Co-Manager 2704 Industrial Drive Jefferson City, MO 65109 Re: K133779 Trade/Device Name: CP Relief Wand ® Model CP-1000 Regulation Number: 21 CFR 882.5890 Regulation Name: Transcutaneous Electrical Nerve Stimulator Regulatory Class: Class II Product Code: GZJ Dated: April 28, 2014 Received: April 29, 2014 Dear Mr. Schroeder: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA’s issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act’s requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical {3} Page 2 – Norm Schroeder device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH’s Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Sincerely yours, Felipe Aguel -S for Carlos L. Peña, PhD, MS Director Division of Neurological and Physical Medicine Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {4} | DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration **Indications for Use** | Form Approved: OMB No. 0910-0120 Expiration Date: January 31, 2017 See PRA Statement below. | | --- | --- | 510(k) Number (if known) K133779 Device Name CP Relief Wand® Model CP-1000 Indications for Use (Describe) The CP Relief Wand® CP-1000 is a TENS Device and is intended for use as an adjunctive therapy for pain management for medical purposes such as symptomatic relief of chronic intractable pain and relief of acute post-surgical and post-traumatic pain. Type of Use (Select one or both, as applicable) ☑ Prescription Use (Part 21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C) PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON A SEPARATE PAGE IF NEEDED. FOR FDA USE ONLY Concurrence of Center for Devices and Radiological Health (CDRH) (Signature) Felipe Aguel -S Date: 2014.05.30 16:11:40 -04'00' This section applies only to requirements of the Paperwork Reduction Act of 1995. "DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW." The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to: Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov "An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number." FORM FDA 3881 (1/14) Page 1 of 1 PSC Publishing Services (701) 441-6740
Innolitics

Panel 1

/
Sort by
Ready

Predicate graph will load when search results are available.

Embedding visualization will load when search results are available.

PDF viewer will load when search results are available.

Loading panels...

Select an item from Submissions

Click any panel, subpart, regulation, product code, or device to see details here.

Section Matches

Results will appear here.

Product Code Matches

Results will appear here.

Special Control Matches

Results will appear here.

Loading collections...